Phase I/II study of CPT-11 plus S-1 in patients with advanced gastric cancer

Komatsu, Y.; Yuuki, S.; Fuse, Nozomu; Takei, Makiko; Miyagishima, Takuto; Kudo, Motonori; Hashino, Satoshi; Asaka, M; Sakata, Yuh

doi:10.1200/jco.2004.22.14_suppl.4191

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17][18][19][20] The difference in TTP between our two groups was about 60 days, but the difference in MST was about 200 days. This may have reflected the effect of second-line chemotherapy with agents such as taxanes or cisplatin and CPT-11, because more patients in the S-1 group received second-line chemotherapy compared with the non-S-1 group (47% vs 26%).…”

Section: Discussionmentioning

confidence: 70%

Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy

et al. 2006

View full text Add to dashboard Cite

Patients treated with S-1 therapy had a better prognosis than patients without S-1. One metastatic site and being given second-line chemotherapy were other factors for better prognosis. For patients with only one metastatic site, a good prognosis can be obtained by second-line chemotherapy for those refractory to S-1. The prognosis of patients who had more than two metastatic sites remained poor; more effective chemotherapy might improve the survival of such patients if they retain good performance status.

show abstract

Section: Discussionmentioning

confidence: 70%